Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

NCT04726241 · View on ClinicalTrials.gov ↗

Study Summary

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Interventions

  • PROCEDURE Biospecimen Collection

Study Locations (20)

California

  • Kaiser Permanente Downey Medical Center — Downey
  • Loma Linda University Medical Center — Loma Linda
  • Miller Children's and Women's Hospital Long Beach — Long Beach
  • Children's Hospital Los Angeles — Los Angeles
  • Valley Children's Hospital — Madera
  • UCSF Benioff Children's Hospital Oakland — Oakland
  • Kaiser Permanente-Oakland — Oakland
  • Children's Hospital of Orange County — Orange
  • Lucile Packard Children's Hospital Stanford University — Palo Alto
  • Rady Children's Hospital - San Diego — San Diego
  • UCSF Medical Center-Mission Bay — San Francisco

Arizona

  • Banner Children's at Desert — Mesa
  • Phoenix Childrens Hospital — Phoenix
  • Banner University Medical Center - Tucson — Tucson

Alabama

  • Children's Hospital of Alabama — Birmingham
  • USA Health Strada Patient Care Center — Mobile

Colorado

  • Children's Hospital Colorado — Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver

Alaska

  • Providence Alaska Medical Center — Anchorage

Arkansas

  • Arkansas Children's Hospital — Little Rock

Trial Details

FieldValue
Enrollment Target 960 participants
Start Date 2022-04-18
Est. Completion 2030-12-31
Phase Phase 1

Sponsor

PedAL BCU

35 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04726241

The ClinicalTrials.gov registry entry for NCT04726241 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PedAL BCU, which has 35 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 8 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention — of which Biospecimen Collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04726241 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Arizona, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04726241 about?

NCT04726241 is a clinical study titled "The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study". This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informati...

What is the current status of trial NCT04726241?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 960 participants. The study started on 2022-04-18. Estimated completion is 2030-12-31.

What conditions does trial NCT04726241 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, Juvenile Myelomonocytic Leukemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04726241?

The interventions under investigation include: Biospecimen Collection (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04726241?

This trial is sponsored by PedAL BCU, which has 35 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04726241 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial